- Israel's Teva Pharmaceutical Industries, with 1995 sales of $668 million, has signed a $70 million syndicated loan to improve its European exposure and to rearrange its debt profile. Dan Suesskind, chief financial officer, arranged the loan with a consortium of 11 European banks. It has a maturity of five years and interest payments of 44 basis points above Libor. It is expected that its drug Copaxone (copolymer-1) for multiple sclerosis will receive US Food and Drug Administration approval in the near future, increasing revenue by an estimated $100 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze